Xilio Therapeutics, Inc.
XLO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $19 | $8 | $3 | $2 |
| % Growth | 135.8% | 175.9% | 70% | – |
| Cost of Goods Sold | $0 | $15 | $0 | $0 |
| Gross Profit | $19 | -$7 | $3 | $2 |
| % Margin | 98.2% | -89.6% | 100% | 100% |
| R&D Expenses | $14 | $15 | $8 | $9 |
| G&A Expenses | $0 | $7 | $9 | $7 |
| SG&A Expenses | $6 | $7 | $9 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$15 | $0 | $0 |
| Operating Expenses | $21 | $7 | $17 | $15 |
| Operating Income | -$2 | -$14 | -$14 | -$14 |
| % Margin | -10.1% | -177.7% | -472.7% | -790.5% |
| Other Income/Exp. Net | -$14 | -$1 | $1 | $1 |
| Pre-Tax Income | -$16 | -$16 | -$13 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$16 | -$13 | -$13 |
| % Margin | -85.4% | -196% | -452.7% | -759.5% |
| EPS | -0.11 | -0.16 | -0.18 | -0.2 |
| % Growth | 31.3% | 11.1% | 10% | – |
| EPS Diluted | -0.11 | -0.16 | -0.18 | -0.2 |
| Weighted Avg Shares Out | 144 | 96 | 75 | 65 |
| Weighted Avg Shares Out Dil | 144 | 96 | 75 | 65 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$16 | -$14 | -$13 | -$13 |
| % Margin | -83.6% | -173% | -455.8% | -768.8% |